![Mark Stejbach](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 975 674 $ al 31/05/2026
Mr. Mark P.
Stejbach is an Independent Non-Executive Director at Indivior Pharmaceuticals, Inc. and an Independent Non-Executive Director at Indivior Ltd. He is on the Board of Directors at Indivior Pharmaceuticals, Inc., Indivior Ltd. and Nirsum Laboratories, Inc. Mr. Stejbach was previously employed as an Independent Non-Executive Director by Flexion Therapeutics, Inc., a Chief Commercial Officer & Senior Vice President by Alkermes Plc, a Chief Commercial Officer by Tengion, Inc., a Principal by Biogen Idec MA, Inc., and a Vice President-Managed Care Marketing by Merck & Co., Inc. He also served on the board at Commonwealth National Fund, Inc. He received his undergraduate degree from Virginia Polytechnic Institute & State University and an MBA from The Wharton School of the University of Pennsylvania.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
0,02 % | 13/05/2026 | 27.087 ( 0,02 % ) | 975 674 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
Indivior Ltd.
 Indivior Ltd. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical drugs | Director/Miembro de la Junta | 24/03/2021 |
Nirsum Laboratories, Inc.
 Nirsum Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Develops new medications for opioid use disorder | Director/Miembro de la Junta | - |
| Empresas | Cargo | Fin |
|---|---|---|
| FLEXION THERAPEUTICS, INC. | Director/Miembro de la Junta | 19/11/2021 |
| ALKERMES PLC | Corporate Officer/Principal | 01/10/2018 |
| TENGION, INC. | Public Communications Contact | 01/01/2012 |
Commonwealth National Fund, Inc.
 Commonwealth National Fund, Inc. Financial ConglomeratesFinance Functions as investment fund | Director/Miembro de la Junta | 01/01/2011 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/07/2008 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 10 |
|---|---|
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Develops and manufactures drugs related to immunology, neurobiology and oncology | Health Technology |
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Tengion, Inc.
 Tengion, Inc. BiotechnologyHealth Technology Develops new human organs and tissues | Health Technology |
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes therapies for the treatment of patients with musculoskeletal conditions | Health Technology |
Indivior Ltd.
Indivior Ltd. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical drugs | Health Technology |
Virginia Polytechnic Institute & State University
 Virginia Polytechnic Institute & State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alkermes Plc
 Alkermes Plc Pharmaceuticals: MajorHealth Technology Manufactures and commercializes pharmaceutical products to treat neurodegenerative disorders and cancer | Health Technology |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Commonwealth National Fund, Inc.
Commonwealth National Fund, Inc. Financial ConglomeratesFinance Functions as investment fund | Finance |
Nirsum Laboratories, Inc.
Nirsum Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Develops new medications for opioid use disorder | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
